LACTOLOGY FOUNDATION

Ranitidine (ATC A02BA02) is an H2-receptor antagonist whose transfer into breast milk is significant and whose long-term use in lactating women requires cautious, individualized risk–benefit assessment. Despite relatively reassuring short-term neonatal safety data, prolonged exposure via breast milk may pose theoretical risks, so shorter courses, evening dosing, and consideration of alternative H2-blockers with lower milk penetration are advisable.

Pharmacology and use

Ranitidine is an antisecretory gastrointestinal drug belonging to the class of H2-receptor antagonists, used to reduce gastric acid secretion. It is indicated for the treatment of erosive esophagitis, active duodenal and benign gastric ulcers, long‑term prophylaxis of duodenal ulcers and gastric hypersecretory states, gastroesophageal reflux disease, stress-ulcer prophylaxis in critically ill patients, heartburn, and as part of combination regimens for Helicobacter pylori eradication.

After oral administration, approximately 50% of the dose is absorbed from the gastrointestinal tract, with only about 15% of absorbed drug bound to plasma proteins. Ranitidine is eliminated mainly by renal excretion and, to a lesser extent, hepatic metabolism, with a plasma half‑life of about 2 hours in adults and neonates with normal renal function, increasing to roughly double this in renal impairment.

Transfer into breast milk

Ranitidine concentrates in breast milk, and its milk levels depend on dose, regimen, lactation stage, and duration of maternal therapy. Reported plasma:milk ratios range from about 1:0.6 after one day of treatment to as high as approximately 1:23.8 after more than two months of continuous therapy, indicating progressive accumulation in milk with long-term use.

At the highest reported plasma:milk ratio, the calculated maximal ranitidine concentration in human milk is around 3.6 mg per liter. Given that the maximal therapeutic dose in neonates is about 0.5 mg/kg/day, an exclusively breastfed infant could receive a dose approaching or exceeding the neonatal therapeutic range under prolonged high maternal exposure, especially in small or preterm infants. Evening administration as a single daily dose before sleep instead of evenly spaced multiple daily doses may reduce peak drug concentrations in milk during the main breastfeeding period, thereby minimizing infant exposure.

Expected neonatal and infant effects

Clinical experience suggests ranitidine is commonly used in pediatric practice, including in newborns, and that infant exposure via breast milk remains below established therapeutic doses in most scenarios. No consistent adverse effects have been reported in breastfed infants whose mothers received ranitidine or other H2 antagonists, although the data set is limited.

Nevertheless, several theoretical or rare risks should be considered, especially with prolonged exposure:

• Potential impairment of vitamin B12 absorption, which could contribute to vitamin B12 deficiency anemia in the infant.
• Possible mild, transient alterations in mental status manifesting as unexplained irritability or crying in preterm infants with immature hepatic metabolism, expected to resolve within 1–2 days after maternal discontinuation.
• In genetically predisposed infants (for example with porphyria), ranitidine could precipitate acute porphyric crises.
• Very rare cardiovascular adverse effects, including bradyarrhythmias, atrioventricular block, or ventricular extrasystoles, with highest concern in infants in the first 30–40 days of life.
• Extremely low but theoretical risks of myelotoxicity, allergic reactions, or small-vessel vasculitis in infants with underlying genetic susceptibility.

By increasing gastric pH, ranitidine can be associated with a higher risk of aspiration of gastric contents and aspiration pneumonia in severe cases, a concern particularly relevant in critically ill patients but conceptually applicable to infants with significant reflux or neurologic impairment.

Lactation-specific classification and risk management

From a lactation-toxicology standpoint, ranitidine is best categorized as a drug with significant passage into breast milk and relative unsuitability for prolonged use during breastfeeding (a relative contraindication rather than an absolute one). In the cited Bulgarian source, ranitidine is assigned a toxico‑lactation Category III, meaning it is relatively unsuitable during lactation and that breastfeeding should ideally be deferred until complete maternal plasma elimination is achieved when high-dose or long-term therapy is needed.

International lactation references, however, generally consider ranitidine compatible with breastfeeding when used at standard doses for short periods, as no adverse effects in breastfed infants have been documented and infant exposure is usually well below therapeutic doses. Among H2 antagonists, famotidine and nizatidine exhibit lower penetration into breast milk and are often suggested as preferred alternatives in nursing mothers, especially for longer treatment courses, whereas ranitidine and cimetidine lead to higher milk levels.

Practical recommendations for use during lactation

When ranitidine is needed in a breastfeeding woman, treatment should use the lowest effective dose and the shortest possible duration to control maternal symptoms. A single evening dose may be preferred over divided doses during the day to reduce peak concentrations in breast milk during periods of intensive breastfeeding. If therapy is anticipated to be long-term or high-dose, switching to an H2 antagonist with lower milk penetration (for example famotidine) or, when appropriate, to a proton pump inhibitor with better lactation data, should be considered.

Breastfed infants of mothers receiving ranitidine should be monitored clinically for normal growth, feeding tolerance, and any unusual symptoms such as unexplained irritability, signs of anemia, or unexpected cardiorespiratory events, although these are not expected under usual conditions. In high‑risk situations (very preterm infants, known genetic disorders, complex comorbidities), temporary interruption of breastfeeding during peak maternal exposure or complete avoidance of ranitidine may be warranted, with individualization based on maternal needs and available alternatives.